Castle Biosciences DecisionDx Melanoma Improves Risk Prediction
Friendswood, Texas, USA, April 21, 2026 In a significant development in precision diagnostics for oncology, Castle Biosciences, Inc. has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Friendswood, Texas, USA, April 21, 2026 In a significant development in precision diagnostics for oncology, Castle Biosciences, Inc. has...
FRIENDSWOOD, Texas, Feb. 19, 2026 — Castle Biosciences announced prospective clinical validation data published in the Journal of the...
FRIENDSWOOD, Texas — December 12, 2025 — Castle Biosciences, Inc., a diagnostics company advancing precision medicine in gastroenterology, announced...
